Prof. Dr. med. Andreas Ramming

Professur für Immunologie der Organschädigung Medizinische Fakultät

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion (2020) Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss M, Heppt F, Meder C, et al. Journal article Ethanol consumption inhibits TFH cell responses and the development of autoimmune arthritis (2020) Azizov V, Dietel K, Steffen F, Dürholz K, Meidenbauer J, Lucas S, Frech M, et al. Journal article Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging (2020) Schmidkonz C, Rauber S, Atzinger A, Agarwal R, Götz TI, Soare A, Cordes M, et al. Journal article Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection (2020) Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss M, Heppt F, Meder C, et al. Conference contribution Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis (2020) Chakraborty D, Zhu H, Juengel A, Summa L, Li YN, Matei AE, Zhou X, et al. Journal article PGC-1α regulates autophagy to promote fibroblast activation and tissue fibrosis (2020) Zhang Y, Shen L, Zhu H, Dreissigacker K, Distler D, Zhou X, Györfi AH, et al. Journal article Large Variability of Frequency and Type of Physical Therapy in Patients in the German Network for Systemic Sclerosis (2020) Belz D, Moinzadeh P, Riemekasten G, Henes J, Müller-Ladner U, Blank N, Koetter I, et al. Journal article DOES ANTI-ACID TREATMENT INFLUENCE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE (SSC-ILD)? DATA FROM THE GERMAN SSC-NETWORK (2020) Kreuter M, Bonella F, Riemekasten G, Mueller-Ladner U, Henes J, Siegert E, Guenther C, et al. Conference contribution REAL-WORLD EFFECTIVENESS AND PERCEIVED USEFULNESS OF SYMPTOM CHECKERS IN RHEUMATOLOGY: INTERIM REPORT FROM THE PROSPECTIVE MULTICENTER BETTER STUDY (2020) Knitza J, Mohn J, Bergmann C, Kampylafka E, Hagen M, Bohr D, Araujo E, et al. Conference contribution FIBROBLAST GROWTH FACTOR RECEPTOR 3 REGULATES THE ACTIVITY OF PROFIBROTIC CYTOKINE AND GROWTH FACTOR PATHWAYS TO DRIVE FIBROBLAST ACTIVATION AND TISSUE FIBROSIS IN SYSTEMIC SCLEROSIS (2020) Chakraborty D, Zhu H, Juengel A, Summa L, Li YN, Bergmann C, Matei AE, et al. Conference contribution